Zacks Investment Research cut shares of Celsion (NASDAQ:CLSN) from a buy rating to a hold rating in a report published on Thursday, January 11th.
According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “
Several other analysts have also recently weighed in on the stock. ValuEngine raised shares of Celsion from a strong sell rating to a sell rating in a report on Saturday, December 9th. Maxim Group upgraded shares of Celsion from a hold rating to a buy rating and set a $7.00 price target on the stock in a research note on Wednesday, October 4th. Finally, Oppenheimer initiated coverage on shares of Celsion in a research note on Tuesday, November 21st. They issued an outperform rating and a $9.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $11.90.
Shares of Celsion (NASDAQ CLSN) traded up $0.03 on Thursday, hitting $2.67. 179,100 shares of the stock traded hands, compared to its average volume of 565,615. The firm has a market capitalization of $43.69, a PE ratio of -0.46 and a beta of 1.22. Celsion has a 1-year low of $1.24 and a 1-year high of $7.56.
Celsion (NASDAQ:CLSN) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.17. Celsion had a negative net margin of 4,292.80% and a negative return on equity of 282.94%. sell-side analysts predict that Celsion will post -2.46 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Celsion stock. Sabby Management LLC acquired a new stake in Celsion Co. (NASDAQ:CLSN) during the second quarter, according to its most recent filing with the SEC. The firm acquired 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned about 1.30% of Celsion at the end of the most recent reporting period. 3.99% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Celsion (CLSN) Rating Lowered to Hold at Zacks Investment Research” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/22/celsion-clsn-lowered-to-hold-at-zacks-investment-research.html.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Get a free copy of the Zacks research report on Celsion (CLSN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.